ClinicalTrials.gg
RecruitingNCT06182293PeriomicrossUpdated Aug 19, 2026

Periodontal Microbiota in Systemic Sclerosis

An interventional study of Subgingival dental plaque sampling for whole metagenome sequencing of the periodontal microbiota in Scleroderma Systemic, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by University Hospital, Strasbourg, France · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years later.
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Systemic sclerosis (SSc) is a rare and complex autoimmune disease. Although its etiology remains unknown, various environmental factors, including certain microorganisms, can represent potential triggers of SSc in individuals with a permissive genetic background. Patients show a wide spectrum of clinical features including periodontitis, which is an inflammatory disease of the tooth-supporting tissues resulting from dysbiosis of the periodontal microbiota guided by inflammophilic bacteria.

The microbiota plays a fundamental role in the induction, training, and function of the host immune system. Numerous studies have highlighted the impact of an altered microbiota, i.e. dysbiosis, on the pathogenesis of immune-mediated diseases. Indeed, commensals are important to maintain immune homeostasis and changes in the microbial composition can be responsible for a loss of tolerance. SSc has been shown to be associated with gut dysbiosis and a depletion of commensals. However, although the oral cavity is one of the two largest microbial habitats, only one study (only focusing on Lactobacillus species) has investigated the oral microbiota in SSc. As periodontal dysbiosis is known to induce low-grade systemic inflammation and represents a risk factor for the development of various autoimmune diseases, the relationship between periodontal microbiota composition and SSc merits further exploration.

The aim of this pilot study is to characterize the taxonomic composition and metabolic pathways of the periodontal microbiota in SSc patients and age and sex-matched controls.

02

Conditions studied

  • Scleroderma Systemic

Browse trials for

03

In context

Scleroderma, Diffuse

310 studies on the registry are indexed under Scleroderma, Diffuse; 76 are open to participants now.

This study's planned enrollment of 30 is below the median of 38 across 227 interventional studies indexed under Scleroderma, Diffuse.

Browse Scleroderma, Diffuse studies →

Lead sponsor

University Hospital, Strasbourg, France is the lead sponsor of 999 studies on the registry; 358 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Common inclusion criteria

  • Men or women over 18 (adults)
  • Affiliation to a social health insurance plan
  • Subject able to understand the aims and risks of the research and to give signed form prior to the inclusion in the study
  • More than 12 teeth suitable for evaluation

Inclusion criteria for systemic sclerosis patients

  • Systemic sclerosis patient with a diagnosis based on the American College of Rheumatology/European League Against Rheumatism criteria (LeRoy et al., 1988 ; van den Hoogen et al., 2013)
  • Diagnosis made during the 2 years preceding study inclusion (early form of the disease)

Inclusion criteria for controls

- Patient attending the Oral Medicine and Surgery Department from the University Hospital of Strasbourg for a routine dental consultation

Exclusion Criteria:

  • - Subject under court protection
  • Subject under guardianship or curatorship
  • Pregnancy or breastfeeding
  • Impossibility to provide accurate information (emergency situation, comprehension difficulties…)
  • Subject currently involved in another clinical trial or in an exclusion period following participation in another clinical trial
  • Smoking (≥ 10 cigarettes per day)
  • Other associated systemic auto-immune disease (Sjögren syndrome with positive serum anti-SSA and/or anti-SSB auto-antibodies, systemic lupus erythematosus…)
  • Progressive chronic illness other than systemic sclerosis
  • Acute infection at inclusion
  • Progressive cancer or cancer diagnosed within 2 years prior to the study
  • Ongoing antibiotic and/or antifungal treatment or within 3 months prior to inclusion
  • Probiotics and/or prebiotics intake within 3 months prior to inclusion
  • Oral antiseptics within the week before inclusion (chlorhexidin mouthwashes…)
  • Risk of infective endocarditis
  • ≥10 mg/day and/or proton pump inhibitors within 3 months prior to inclusion
  • Previous hematopoietic stem cell transplantation
  • Another cause of skin sclerosis (radiotherapy of the orofacial area…)
  • Periodontal specialized treatments, root and/or periodontal surgical treatment and/or subgingival instrumentation within the year before inclusion
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Other
    Systemic sclerosis

    Other: Subgingival dental plaque sampling for whole metagenome sequencing of the periodontal microbiota

  • Other
    Controls

    Other: Subgingival dental plaque sampling for whole metagenome sequencing of the periodontal microbiota

Interventions

  • OtherSubgingival dental plaque sampling for whole metagenome sequencing of the periodontal microbiota

    Subgingival plaque will be collected at 6 sites using sterile curettes after removal of supragingival biofilm by brushing. After microbial DNA extraction, whole metagenome will be sequenced.

06

What researchers measure

Primary outcomes

  1. Alpha diversity of the periodontal microbiota using Chao-1 index

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06182293
Responsible party
Sponsor
First posted
Dec 26, 2023
Start date
Oct 24, 2024
Primary completion
Oct 24, 2027 (estimated)
Completion
Oct 24, 2027 (estimated)
Last update
Aug 19, 2026

Study contacts

Sophie JUNG, MD
Contact
sophie.jung1@chru-strasbourg.fr
03.88.11.69.10

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion